Lv4
500 积分 2021-01-12 加入
CRISPR therapies march into clinic, but genotoxicity concerns linger
11个月前
已完结
Site-directed RNA editing by harnessing ADARs: advances and challenges
1年前
已完结
Uncovering the mode of action of engineered T cells in patient cancer organoids
1年前
已完结
T cell-engaging therapies — BiTEs and beyond
1年前
已完结
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
1年前
已完结
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform
1年前
已完结
Trans ‐synaptic mechanisms orchestrated by mammalian synaptic cell adhesion molecules
1年前
已完结
Bispecific Complement Engagers for Targeted Complement Activation
1年前
已完结
Cancer-inducing niche: the force of chronic inflammation
1年前
已完结
CRISPR/Cas9 as precision and high-throughput genetic engineering tools in gastrointestinal cancer research and therapy
1年前
已完结
皖公网安备34019202002308
